The very detailed serological analysis of CP from the early days of the pandemic provided by Zhang et al. (3) suggests a roadmap for future deployments of CP, whether against influenza or against another coronavirus, and, in that eventuality, suggest the following best practices from the COVID-19 experience (Fig. 1). Here, CP is linked to influenza.